Common Contracts

] Shares of Common Stock Pre-Funded Warrants to Purchase [ ] Shares of Common Stock and Warrants to Purchase [ ] Shares of Common Stock Onconova Therapeutics, Inc. UNDERWRITING AGREEMENT

Underwriting Agreement • November 12th, 2019 • Onconova Therapeutics, Inc. • Pharmaceutical preparations

• Contract Type
  Underwriting Agreement
• Filed
  November 12th, 2019
• Company
  Onconova Therapeutics, Inc.
• Industry
  Pharmaceutical preparations

Onconova Therapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) an aggregate of [ ] Units (as defined below) and [ ] Pre-Funded Units (as defined below) representing (i) an aggregate of (a) [ ] shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (“Common Stock”) and (b) pre-funded warrants to purchase [ ] shares of Common Stock at an exercise price of $0.0001 per share (the “Pre-Funded Warrants”); and (ii) warrants (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”) to purchase an aggregate of [ ] shares Common Stock. The amount and form of the Firm Securities to be purchased by the Underwriter is set forth opposite its name on Schedule I hereto. The Company also proposes to sell to the Underwriter, at the option of the Underwriter, up to an additional [ ] shares of Common Stock (the “Option Shares”) and/or wa

5,707,500 Shares of Common Stock Pre-Funded Warrants to Purchase 2,942,500 Shares of Common Stock and 8,650,000 Warrants to Purchase 865,000 Shares of Series A Convertible Preferred Stock Onconova Therapeutics, Inc. UNDERWRITING AGREEMENT

Underwriting Agreement • February 8th, 2018 • Onconova Therapeutics, Inc. • Pharmaceutical preparations

• Contract Type
  Underwriting Agreement
• Filed
  February 8th, 2018
• Company
  Onconova Therapeutics, Inc.
• Industry
  Pharmaceutical preparations

Onconova Therapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to H.C. Wainwright & Co., LLC (the “Underwriter”) an aggregate of 5,707,500 Units (as defined below) and 2,942,500 Pre-Funded Units (as defined below) representing (i) an aggregate of (a) 5,707,500 shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (“Common Stock”) and (b) pre-funded warrants to purchase 2,942,500 shares of Common Stock at an exercise price of $0.01 per share (the “Pre-Funded Warrants”); and (ii) 8,650,000 warrants (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”) to purchase an aggregate of 865,000 shares of the Series A Convertible Preferred Stock, par value $0.01 per share, of the Company (“Series A Preferred Stock”). The amount and form of the Firm Securities to be purchased by the Underwriter is set forth opposite its name on Schedule I hereto. The Company also proposes t